{"id":15029,"date":"2023-06-13T12:00:55","date_gmt":"2023-06-13T10:00:55","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=15029"},"modified":"2023-06-13T11:26:37","modified_gmt":"2023-06-13T09:26:37","slug":"jena-based-biotechnology-company-dynamic42-raises-mid-seven-figure-investment-in-series-a-financing-round","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2023-en\/jena-based-biotechnology-company-dynamic42-raises-mid-seven-figure-investment-in-series-a-financing-round\/","title":{"rendered":"Jena-based biotechnology company \u201cDynamic42\u201d raises mid-seven-figure investment in Series A financing round"},"content":{"rendered":"<p><strong>Inno\u00adv\u00ada\u00adtive organ-on-chip spe\u00adcial\u00adist Dynamic42 GmbH has closed a mid-seven-fig\u00adure financ\u00ading round. The com\u00adpany, which was spun off from the \u201cCen\u00adter of Sep\u00adsis Con\u00adtrol and Care\u201d of the Uni\u00adver\u00adsity Hos\u00adpi\u00adtal Jena in March 2018, was able to con\u00advince both the pre\u00advi\u00adous lead investor bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm\u2011t) and a fam\u00adily office from the health sec\u00adtor to invest and sup\u00adport the growth, devel\u00adop\u00adment and vision of the com\u00adpany in the com\u00ading years as part of a growth financ\u00ading round (Series A).&nbsp;<\/strong><\/p>\n<p>Deci\u00adsive for the invest\u00adment was above all the added value that Dynamic42 gen\u00ader\u00adates with its tech\u00adnol\u00adogy and its use for soci\u00adety, such as the increase of drug safety, the reduc\u00adtion of drug devel\u00adop\u00adment costs and the reduc\u00adtion of ani\u00admal test\u00ading. Here, Dynamic42\u00b4s tech\u00adnol\u00adogy offers a very good alter\u00adna\u00adtive to cur\u00adrent sys\u00adtems used in the devel\u00adop\u00adment of active com\u00adpounds and has a high mar\u00adket poten\u00adtial. \u201cWe can proudly announce that we have cre\u00adated an up-and-com\u00ading com\u00adpany and are extremely pleased about this strate\u00adgi\u00adcally impor\u00adtant invest\u00adment. In times of a more chal\u00adleng\u00ading invest\u00adment mar\u00adket, it is a strong sig\u00adnal for us that our tech\u00adnol\u00adogy and vision pos\u00adsess high poten\u00adtial,\u201d said Man\u00adag\u00ading Direc\u00adtors Dr. Mar\u00adtin Raasch and Dr. Knut Rennert.<\/p>\n<p><strong>Flex\u00adi\u00adble and cus\u00adtomized Organ-on-Chip Solu\u00adtions for Advanced Drug Testing<\/strong><\/p>\n<p>Dynamic42 offers its cus\u00adtomers minia\u00adtur\u00adized human organ mod\u00adels (so-called organ-on-chip\/ micro\u00adphys\u00adi\u00ado\u00adlog\u00adi\u00adcal sys\u00adtems) for drug test\u00ading. Dynamic42 is unique on the mar\u00adket due to its flex\u00adi\u00adble and eas\u00adily cre\u00adated cus\u00adtomer-spe\u00adcific solu\u00adtions based on its inno\u00adv\u00ada\u00adtive tech\u00adnol\u00adogy plat\u00adform. In addi\u00adtion, Dynamic42 is able to inte\u00adgrate essen\u00adtial com\u00adpo\u00adnents of the human immune sys\u00adtem into its human organ mod\u00adels and to inves\u00adti\u00adgate their influ\u00adence on drug com\u00adpat\u00adi\u00adbil\u00adity. Cus\u00adtomers can thus make ini\u00adtial judge\u00adments about the tox\u00adi\u00adc\u00adity of drug can\u00addi\u00addates in humans even before ani\u00admal test\u00ading in the pre\u00adclin\u00adi\u00adcal phase of drug devel\u00adop\u00adment and decide whether to con\u00adtinue or stop the devel\u00adop\u00adment of an active substance.<\/p>\n<p>\u201cDynamic42 GmbH has grown steadily since it was founded five years ago and has already been able to win well-known phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies as cus\u00adtomers. We are con\u00advinced that Dynamic42, with its strong tech\u00adnol\u00adogy plat\u00adform and moti\u00advated team, will play a lead\u00ading role in the rapidly grow\u00ading organ-on-chip mar\u00adket in the future,\u201d said Ste\u00adfan Jahn, Senior Invest\u00adment Man\u00adager at bm\u2011t.<\/p>\n<p>With the invest\u00adment, Dynamic42 will con\u00adtinue the fur\u00adther devel\u00adop\u00adment of prod\u00aducts and ser\u00advices, open new mar\u00adkets, recruit highly qual\u00adi\u00adfied per\u00adson\u00adnel, fur\u00adther develop the com\u00adpany infra\u00adstruc\u00adture as well as expand the prop\u00aderty rights port\u00adfo\u00adlio and sales infra\u00adstruc\u00adture. An impor\u00adtant mile\u00adstone in the com\u00ading years will be the company\u00b4s inter\u00adna\u00adtion\u00adal\u00adiza\u00adtion, includ\u00ading enter\u00ading the USA as the world\u2019s largest phar\u00adma\u00adceu\u00adti\u00adcal market.<\/p>\n<h4><strong>About Dynamic42 GmbH<\/strong><\/h4>\n<p>Dynamic42 GmbH was founded in 2018 and is a spin-off from the Inte\u00adgrated Research and Treat\u00adment Cen\u00adter for Sep\u00adsis Con\u00adtrol and Care (CSCC) of the Uni\u00adver\u00adsity Hos\u00adpi\u00adtal Jena. Dynamic42 mar\u00adkets and devel\u00adops human organ-on-chip models\/ micro\u00adphys\u00adi\u00ado\u00adlog\u00adi\u00adcal sys\u00adtems with inte\u00adgrated immune sys\u00adtem com\u00adpo\u00adnents for research and test\u00ading of phar\u00adma\u00adceu\u00adti\u00adcal prod\u00aducts, novel ther\u00ada\u00adpies such as nanopar\u00adti\u00adcles, chem\u00adi\u00adcal and food additives.<\/p>\n<h4><strong>About bm\u2011t<\/strong><\/h4>\n<p>bm\u2011t is one of the top addresses for invest\u00adments in Thuringia. The entrusted cap\u00adi\u00adtal is prof\u00aditably invested by bm\u2011t in start-up teams and com\u00adpa\u00adnies in the Free State of Thuringia. bm\u2011t cur\u00adrently man\u00adages eleven funds with a total vol\u00adume of over 415 mil\u00adlion euros and invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies in almost all sec\u00adtors and in all phases of cor\u00adpo\u00adrate devel\u00adop\u00adment \u2014 from the start-up and growth phases to com\u00adpany suc\u00adces\u00adsions and buyouts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm\u2011t) and a fam\u00adily office from the health sec\u00adtor invest a mid-seven-fig\u00adure invest\u00adment in organ-on-chip spe\u00adcial\u00adist Dynamic42 GmbH.<\/p>\n","protected":false},"author":2,"featured_media":15027,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[234],"tags":[176,177,210,159,171],"class_list":["post-15029","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2023-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=15029"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/15027"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=15029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=15029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=15029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}